Related references
Note: Only part of the references are listed.Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape
Sara Hamis et al.
PLOS COMPUTATIONAL BIOLOGY (2020)
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect
Cho Rong Hong et al.
NEOPLASIA (2019)
Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
Linda Spiegelberg et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2019)
Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning
Sigrid A. Langhans
FRONTIERS IN PHARMACOLOGY (2018)
Unexpected pharmacokinetics of evofosfamide observed in phase III MAESTRO study.
Jack P. Higgins et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
William D. Tap et al.
LANCET ONCOLOGY (2017)
A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the Low Drug Uptake Volume
Ala Yaromina et al.
RADIOTHERAPY AND ONCOLOGY (2017)
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Francis W. Hunter et al.
BRITISH JOURNAL OF CANCER (2016)
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Roger M. Phillips
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma
Maria R. Abbattista et al.
CANCER BIOLOGY & THERAPY (2015)
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs
Francis W. Hunter et al.
CANCER RESEARCH (2015)
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging
Sarah G. J. A. Peeters et al.
CLINICAL CANCER RESEARCH (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Mitesh J. Borad et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response
Sanaz Yahyanejad et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva et al.
HAEMATOLOGICA (2015)
Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer
Francis W. Hunter et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000
Robert F. Anderson et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2014)
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Christopher P. Guise et al.
CHINESE JOURNAL OF CANCER (2014)
Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
Jessica D. Sun et al.
CLINICAL CANCER RESEARCH (2012)
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Fanying Meng et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia
Christopher P. Guise et al.
MOLECULAR PHARMACOLOGY (2012)
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
Mark J. McKeage et al.
BMC CANCER (2011)
A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity
Kashyap Patel et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy
Yongchuan Gu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
Kristen N. Ganjoo et al.
ONCOLOGY (2011)
Targeting hypoxia in cancer therapy
William R. Wilson et al.
NATURE REVIEWS CANCER (2011)
DNA interstrand crosslink repair and cancer
Andrew J. Deans et al.
NATURE REVIEWS CANCER (2011)
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
Michael B. Jameson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3
Christopher P. Guise et al.
CANCER RESEARCH (2010)
Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and Humans
Yongchuan Gu et al.
DRUG METABOLISM AND DISPOSITION (2010)
Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A
Yongchuan Gu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis
Lane Birtwistle et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2009)
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: Comparison of the dinitrobenzamide mustard PR-104A and tirapazamine
Kevin O. Hicks et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A:: A role for NADPH:cytochrome P450 oxidoreductase under hypoxia
Chris P. Guise et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104
Adam V. Patterson et al.
CLINICAL CANCER RESEARCH (2007)
Synthesis of asymmetric halomesylate mustards with aziridineethanol/alkali metal halides: application to an improved synthesis of the hypoxia prodrug PR-104
Shangjin Yang et al.
TETRAHEDRON (2007)
Synthesis of 3H- and 2H4-labelled versions of the hypoxia-activated pre-prodrug 2-((2-bromoethyl)-2,4-dinitro-6-(((2-(phosphonooxy)ethyl)amino)carbonyl)anilino)ethyl methanesulfonate (PR-104)
Graham J. Atwell et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2007)
Hypoxia in cancer: significance and impact on clinical outcome
Peter Vaupel et al.
CANCER AND METASTASIS REVIEWS (2007)
Bystander effects of bioreductive drugs: Potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards
William R. Wilson et al.
RADIATION RESEARCH (2007)
Tumor hypoxia:: Definitions and current clinical, biologic, and molecular aspects
M Höckel et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
